IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer.

In conclusion, even though the cancer grows slower in IL-33 deficient mice, the data that IL-33 deficiency does not protect against AKI in a clinically relevant model, suggest that IL-33 inhibition may not be useful to attenuate AKI in patients with cancer. However, serum IL-33 may serve as a biomarker of AKI.
PMID: 29070568 [PubMed - as supplied by publisher]

Source: Am J Physiol Renal P... - October 25, 2017 Category: Urology & Nephrology Authors: Ravichandran K, Holditch S, Brown CN, Wang Q, Ozkok A, Weiser-Evans MC, Nemenoff RA, Miyazaki M, Thiessen-Philbrook H, Parikh CR, Ljubanovic D, Edelstein CL Tags: Am J Physiol Renal Physiol Source Type: research